Initially developed as a treatment for Type 2 diabetes, the drug gained widespread attention after clinical trials showed it reduced baseline body weight by approximately 10%-15%
Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, Joles JA, van Raalte DH
With the massive surge in the use of GLP-1 medications like Semaglutide and Tirzepatide, more people than ever are achieving their goal weight
Be among the first to know when we release our MAB specials, and stay up-to-date on everything going on during our biggest savings week of the year
Additionally, Michigan and California had the highest rates of non-preferred AP use among patients with SMI, surpassing the rates observed in Illinois, Wisconsin, Colorado, and Florida ( Table 1 )
Face photos reveal reduced puffiness, more defined jawlines, and decreased fat around the neck and cheeks